手术切除术与脾多肽联合化疗对胰腺癌的疗效分析
|
摘要
目的探讨手术切除术与脾多肽联合化疗对胰腺癌的疗效。方法选取胰腺癌患者82例,对其临床资料进行回顾性分析,按不同的治疗方式进行分组,行手术切除术的患者为对照组,脾多肽联合化疗的患者为观察组,分析两组患者在治疗后的有效率、不良反应率及生活质量。结果对照组治疗有效率为85. 3%,观察组治疗有效率为83. 3%,两组比较差异无统计学意义(P> 0. 05);对照组不良反应率为63. 6%,对照组不良反应率为64. 9%,两组比较差异无统计学意义(P> 0. 05);对照组患者KPS评分增加率为52. 9%,观察组患者KPS评分增加率为43. 7%,两组生活质量比较差异具有统计学意义(P <0. 05)。结论手术切除术与脾多肽联合化疗在胰腺癌治疗中的疗效及不良反应率无明显差异,脾多肽联合化疗治疗胰腺癌可有效改善临床症状,减轻化疗所带来的不良反应。
Objective To investigate the different curative effects of surgical resection and splenic polypeptide combined with chemotherapy in the treatment of pancreatic cancer. Methods A total of 82 patients with pancreatic cancer were enrolled.The clinical data were retrospectively analyzed. The patients were divided into groups according to different treatment methods.The patients who underwent surgical resection were the control group. The patients with spleen peptide combined with chemotherapy were the observation group. Efficiency after treatment,adverse reaction rate and quality of life. Results The effective rate was85. 3% in the control group and 83. 3% in the observation group. There was no significant difference between the two groups( P> 0. 05). The adverse reaction rate was 63. 6% in the control group and 64. 9% in the control group. There was no significant difference between the two groups( P > 0. 05). The increase rate of KPS score was 52. 9% in the control group and 43. 7% in the observation group. The difference in quality of life between the two groups was statistically significant( P < 0. 05). Conclusion There is no significant difference in the efficacy and adverse reaction rate between surgical resection and spleen peptide chemotherapy in the treatment of pancreatic cancer. Spleen polypeptide combined with chemotherapy for pancreatic cancer can effectively improve clinical symptoms and reduce the adverse reactions caused by chemotherapy.
Objective To investigate the different curative effects of surgical resection and splenic polypeptide combined with chemotherapy in the treatment of pancreatic cancer. Methods A total of 82 patients with pancreatic cancer were enrolled.The clinical data were retrospectively analyzed. The patients were divided into groups according to different treatment methods.The patients who underwent surgical resection were the control group. The patients with spleen peptide combined with chemotherapy were the observation group. Efficiency after treatment,adverse reaction rate and quality of life. Results The effective rate was85. 3% in the control group and 83. 3% in the observation group. There was no significant difference between the two groups( P> 0. 05). The adverse reaction rate was 63. 6% in the control group and 64. 9% in the control group. There was no significant difference between the two groups( P > 0. 05). The increase rate of KPS score was 52. 9% in the control group and 43. 7% in the observation group. The difference in quality of life between the two groups was statistically significant( P < 0. 05). Conclusion There is no significant difference in the efficacy and adverse reaction rate between surgical resection and spleen peptide chemotherapy in the treatment of pancreatic cancer. Spleen polypeptide combined with chemotherapy for pancreatic cancer can effectively improve clinical symptoms and reduce the adverse reactions caused by chemotherapy.
引文
[1]李晶,张春莲,方彩云.米非司酮、宫腔镜联合腹腔镜技术用于剖宫产术后子宫瘢痕妊娠治疗的安全性研究〔J〕.空军医学杂志,2017,33(2):136-138.
[2]黄玮,高立,张永利.宫颈癌根治术腹腔镜与开腹手术的临床对照研究〔J〕.实用癌症杂志,2017,32(12):2061-2063.
[3]别玉坤,冯以斌,杨成林.腹腔镜下规则性肝切除与肝肿瘤剥除术治疗肝血管瘤的临床疗效比较〔J〕.实用癌症杂志,2017,32(12):1993-1995.
[4]李敬,刘定海,邹宁,等. HIF-2α、VEGF、COX-2、MMP-9表达及其与肾细胞癌血管生成的关系分析〔J〕.标记免疫分析与临床,2017,24(11):1243-1246.
[5]徐海波,熊异平,余恒勇.膀胱癌组织中MMP-2、MMP-9、Survivin、Livin和VEGF表达的临床意义分析〔J〕.标记免疫分析与临床,2017,24(01):51-54.
[6]严虹霞,杜娟,柴丽敏,等.不同免疫增强剂对肿瘤患者免疫功能的影响〔J〕.中国医院药学杂志,2017,37(5):454-458.
[7] Dokmak S,Aussilhou B,FtRiche F S,et al. Robot-assisted Minimally Invasive Distal Pancreatectomy Is Superior to the Laparoscopic Technique〔J〕. Annals of Surgery,2016,257(1):128-132.
[8]刘音吟,谈勇,徐菊芳.地屈孕酮对多囊卵巢综合征妊娠大鼠种植窗期PR、ICAM-1的影响〔J〕.东南大学学报(医学版),2016,35(4):514-518.
[9] Qiu W,Christakis I,Silva A,et al. Utility of chromogranin A,pancreatic polypeptide,glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients〔J〕. Clinical Endocrinology,2016,85(3):400-407.
[10] Reinehr T,Roth CL. The gut sensor as regulator of body weight〔J〕. Endocrine,2015,49(1):1-16.
[2]黄玮,高立,张永利.宫颈癌根治术腹腔镜与开腹手术的临床对照研究〔J〕.实用癌症杂志,2017,32(12):2061-2063.
[3]别玉坤,冯以斌,杨成林.腹腔镜下规则性肝切除与肝肿瘤剥除术治疗肝血管瘤的临床疗效比较〔J〕.实用癌症杂志,2017,32(12):1993-1995.
[4]李敬,刘定海,邹宁,等. HIF-2α、VEGF、COX-2、MMP-9表达及其与肾细胞癌血管生成的关系分析〔J〕.标记免疫分析与临床,2017,24(11):1243-1246.
[5]徐海波,熊异平,余恒勇.膀胱癌组织中MMP-2、MMP-9、Survivin、Livin和VEGF表达的临床意义分析〔J〕.标记免疫分析与临床,2017,24(01):51-54.
[6]严虹霞,杜娟,柴丽敏,等.不同免疫增强剂对肿瘤患者免疫功能的影响〔J〕.中国医院药学杂志,2017,37(5):454-458.
[7] Dokmak S,Aussilhou B,FtRiche F S,et al. Robot-assisted Minimally Invasive Distal Pancreatectomy Is Superior to the Laparoscopic Technique〔J〕. Annals of Surgery,2016,257(1):128-132.
[8]刘音吟,谈勇,徐菊芳.地屈孕酮对多囊卵巢综合征妊娠大鼠种植窗期PR、ICAM-1的影响〔J〕.东南大学学报(医学版),2016,35(4):514-518.
[9] Qiu W,Christakis I,Silva A,et al. Utility of chromogranin A,pancreatic polypeptide,glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients〔J〕. Clinical Endocrinology,2016,85(3):400-407.
[10] Reinehr T,Roth CL. The gut sensor as regulator of body weight〔J〕. Endocrine,2015,49(1):1-16.